126 related articles for article (PubMed ID: 34162561)
21. Tumor markers in lung cancer: does the method of obtaining the cut-off point and reference population influence diagnostic yield?
Pina TC; Zapata IT; López JB; Pérez JL; Paricio PP; Hernández PM
Clin Biochem; 1999 Aug; 32(6):467-72. PubMed ID: 10667483
[TBL] [Abstract][Full Text] [Related]
22. The expression of CD markers in solid tumors: Significance in metastasis and prognostic value.
Rezaeeyan H; Shahrabi S; McKee TD; Saki N
Histol Histopathol; 2018 Oct; 33(10):1005-1012. PubMed ID: 29508889
[TBL] [Abstract][Full Text] [Related]
23. PIVKA-II: A biomarker for diagnosing and monitoring patients with pancreatic adenocarcinoma.
Tartaglione S; Mancini P; Viggiani V; Chirletti P; Angeloni A; Anastasi E
PLoS One; 2021; 16(5):e0251656. PubMed ID: 34015010
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathological and prognostic significance of homeobox transcript antisense RNA expression in various cancers: A meta-analysis.
Min SN; Wei T; Wang XT; Wu LL; Yu GY
Medicine (Baltimore); 2017 Jun; 96(23):e7084. PubMed ID: 28591050
[TBL] [Abstract][Full Text] [Related]
25. Clinical significance of AFP and PIVKA-II responses for monitoring treatment outcomes and predicting prognosis in patients with hepatocellular carcinoma.
Park H; Park JY
Biomed Res Int; 2013; 2013():310427. PubMed ID: 24455683
[TBL] [Abstract][Full Text] [Related]
26. [Generalized ROC criteria in the evaluation of several tumor markers].
Kramar A; Faraggi D; Ychou M; Reiser B; Grenier J
Rev Epidemiol Sante Publique; 1999 Sep; 47(4):376-83. PubMed ID: 10519178
[TBL] [Abstract][Full Text] [Related]
27. Gene-expression profiling to predict responsiveness to immunotherapy.
Jamieson NB; Maker AV
Cancer Gene Ther; 2017 Mar; 24(3):134-140. PubMed ID: 27834354
[TBL] [Abstract][Full Text] [Related]
28. Clinical significance of blood-based miRNAs as diagnostic and prognostic nucleic acid markers in breast cancer: Comparative to conventional tumor markers.
Swellam M; Ramadan A; El-Hussieny EA; Bakr NM; Hassan NM; Sobeih ME; EzzElArab LR
J Cell Biochem; 2019 Aug; 120(8):12321-12330. PubMed ID: 30825229
[TBL] [Abstract][Full Text] [Related]
29. Tumor marker levels before and after curative treatment of hepatocellular carcinoma as predictors of patient survival.
Nanashima A; Taura N; Abo T; Ichikawa T; Sakamoto I; Nagayasu T; Nakao K
Dig Dis Sci; 2011 Oct; 56(10):3086-100. PubMed ID: 21706206
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic value of prothrombin induced by the absence of vitamin K or antagonist-II (PIVKA-II) for early stage HBV related hepatocellular carcinoma.
Wang X; Zhang W; Liu Y; Gong W; Sun P; Kong X; Yang M; Wang Z
Infect Agent Cancer; 2017; 12():47. PubMed ID: 28852419
[TBL] [Abstract][Full Text] [Related]
31. The potential role of intrinsic hypoxia markers as prognostic variables in cancer.
Moon EJ; Brizel DM; Chi JT; Dewhirst MW
Antioxid Redox Signal; 2007 Aug; 9(8):1237-94. PubMed ID: 17571959
[TBL] [Abstract][Full Text] [Related]
32. Predictive value of protein induced by absence of vitamin K absence or antagonist II, alpha-fetoprotein and gamma-glutamyltransferase/aspartate aminotransferase ratio for the diagnosis of hepatocellular carcinoma in transplantation candidates.
Ekmen N; Akalin Ç; Akyildiz M
Eur J Gastroenterol Hepatol; 2021 Feb; 32(2):294-299. PubMed ID: 32796360
[TBL] [Abstract][Full Text] [Related]
33. A system for tumor heterogeneity evaluation and diagnosis based on tumor markers measured routinely in the laboratory.
Hui L; Rixv L; Xiuying Z
Clin Biochem; 2015 Dec; 48(18):1241-5. PubMed ID: 26216289
[TBL] [Abstract][Full Text] [Related]
34. HtrA1 as a promising tissue marker in cancer: a meta-analysis.
Altobelli E; Angeletti PM; Morroni M; Profeta VF
BMC Cancer; 2018 Feb; 18(1):143. PubMed ID: 29409460
[TBL] [Abstract][Full Text] [Related]
35. Mathematical model application to the kinetic study of tumor markers.
Cappelli G
Int J Biol Markers; 1994; 9(1):8-14. PubMed ID: 8051436
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathological and prognostic value of SNHG6 in cancers: a systematic review and a meta-analysis.
Zhang S; Qiu D; Xie X; Shen Y
BMC Cancer; 2020 Apr; 20(1):343. PubMed ID: 32321469
[TBL] [Abstract][Full Text] [Related]
37. Predicting prostate cancer risk through incorporation of prostate cancer gene 3.
Ankerst DP; Groskopf J; Day JR; Blase A; Rittenhouse H; Pollock BH; Tangen C; Parekh D; Leach RJ; Thompson I
J Urol; 2008 Oct; 180(4):1303-8; discussion 1308. PubMed ID: 18707724
[TBL] [Abstract][Full Text] [Related]
38. [Predictive biomarkers for tumor-relevant signaling pathways in molecular pathology].
Bonzheim I; Fend F
Pathologe; 2014 Feb; 35(1):93-105. PubMed ID: 24496994
[TBL] [Abstract][Full Text] [Related]
39. Expression of TIP60 (tat-interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatment-specific outcome of localised invasive bladder cancer.
Laurberg JR; Brems-Eskildsen AS; Nordentoft I; Fristrup N; Schepeler T; Ulhøi BP; Agerbaek M; Hartmann A; Bertz S; Wittlinger M; Fietkau R; Rödel C; Borre M; Jensen JB; Orntoft T; Dyrskjøt L
BJU Int; 2012 Dec; 110(11 Pt C):E1228-36. PubMed ID: 23046361
[TBL] [Abstract][Full Text] [Related]
40. Novel Long Non-coding RNA Markers for Prognostic Prediction of Patients with Bladder Cancer.
Li WX; Zhang YL
Chin Med Sci J; 2020 Sep; 35(3):239-247. PubMed ID: 32972501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
